Trovagene, Inc.

Diamir, LLC

Xenomics, Inc.

Samuil R Umansky

Hovsep S Melkonyan

Kira S Sheinerman

Vladimir G Tsivinsky

Angela Cannas

Louis David Tomei

Erik Meyer

William John Feaver

Zhenghan M Xin

Anatoly V Lichtenstein

Vladimir S Scheinker

Eugene M Shekhtman

Hovsep Milkonyan

Vladimir Tsivinsky

Kirsa S Sheinerman

Hovsep Melkonyan

Zhenghan Xin

The invention is directed to methods for diagnosis and differentiation of neurodegenerative diseases (NDs), by quantifying miRNAs in bodily fluids.

Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases

The invention is directed to methods for early diagnosis, progression and treatment monitoring of Parkinson's disease (PD) and its differentiation from other neurodegenerative diseases by quantifying brain-enriched miRNA in bodily fluids.

Methods of using miRNAs from bodily fluids for detection and monitoring of Parkinson's disease (PD)

The invention provides methods for diagnosis and monitoring of Rett syndrome and other neurodevelopmental disorders by quantitative analysis of miRNAs in bodily fluids.

Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders

The present invention is directed to methods for detection, treatment monitoring, and slowing of aging by quantifying miRNAs in bodily fluids.

miRNA-based methods for detecting and monitoring aging

Described are methods for early noninvasive or minimally invasive detection of pathological changes in organ systems/organs/tissues/cells by quantifying organ system-/organ-/tissue-/cells type-enriched miRNA in bodily fluids.

miRNA-based universal screening test (UST)

Described are methods for early diagnosis and progression monitoring of Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) by quantifying neurite and/or synapse miRNAs in bodily fluids.

Methods of using miRNA from bodily fluids for early detection and monitoring of mild cognitive impairment (MCI) and Alzheimer's disease (AD)

This invention provides compositions and methods for rapid separation, isolation and purification of nucleic acids from biological samples using anionic exchange media. The method can utilize commercially available strong or weak anion exchanger materials with selected solutions of known ionic strength for adsorption and elution. The instant method is particularly advantageous as it permits the purification and identification of shorter fragments of nucleic acids from bodily fluids which, until now, had not been identified.

Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media

The present invention provides highly sensitive methods used for diagnosing and monitoring various diseases and disorders by detecting and analyzing 'ultra short' (20-50 base pair) nucleic acids obtained from bodily fluids.

Amplification and sequencing of transrenal nucleic acids

Methods of using miRNA from bodily fluids for early detection and monitoring of mild cognitive impairment (MCI) and alzheimer's disease (AD)

The invention provides compositions and methods for the differential detection of high risk forms of HPV from a urine sample provided by a patient. Specifically, the invention provides primers and probes that specifically recognize and bind sequences within the E1 gene of HPV. Detection of high risk forms of HPV identifies individuals at risk of developing or in the early stages of cervical carcinoma.

Method for detection of high risk human papillomavirus

This invention provides compositions and methods for rapid isolation and purification of nucleopolymers from biological samples using anionic exchange media. The method of this invention can utilize commercially available anion exchanger materials with selected solutions of known ionic strength for absorption and elution. The medium/nucleoprotein bound complex may be optionally stored or transported, and is subsequently treated with eluents to remove undesirable proteins and inorganic salts. The partially purified complex may also be stored or transported. This method is particularly advantageous since it allows rapid isolation and purification of soluble nucleic acids from a large volume of biological fluids with easy handling and storage, stabilizing the samples against degradation prior to analysis. It also permits the purification and identification of shorter fragments of nucleic acids from bodily fluids which, until now, had not been identified. The method is widely useful to prepare samples formats that are convenient in diagnostic analytical methods.

Described are methods for detection of neuronal pathologies using quantitative analysis in bodily fluids of synapse and/or neurite small RNAs and application of these methods to early diagnosis and monitoring of neurodegenerative diseases and other neurological disorders.

Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases

The invention provides compositions and methods for the differential detection of high risk forms of HPV from a urine sample provided by a patient. Specifically, the invention provides primers and probes that specifically recognize and bind sequences within the Egene of HPV. Detection of high risk forms of HPV identify individuals at risk of developing or in the early stages of cervical carcinoma.

Genetic marker for detection of human papillomavirus

Described are non-invasive methods of detecting in vivo cell death by measuring levels of ubiquitous and tissue specific miRNA. The method can be applied for detection of pathologies caused or accompanied by cell death, as well as for diagnosis of infectious disease, cytotoxic effects induced by different chemical or physical factors, and the presence of specific fetal abnormalities.

Growing community of inventors

Princeton, NJ, United States of America

Samuil R Umansky